Analysis of Global Research on Malaria and Plasmodium vivax

José Antonio Garrido-Cardenas 1, José Cebrián-Carmona 1, Lilia González-Cerón 2, Francisco Manzano-Agugliaro 3,* and Concepción Mesa-Valle 1

1 Department of Biology and Geology, University of Almeria, 04120 Almeria, Spain; jcardena@ual.es (J.A.G.-C.); pepe_cebri@hotmail.com (J.C.-C.); cmesa@ual.es (C.M.-V.)
2 Regional Center for Public Health Research, National Institute of Public Health, Tapachula, Chiapas 30700, Mexico; lgonzal@insp.mx
3 Department of Engineering, University of Almeria, CeiA3, 04120 Almeria, Spain
* Correspondence: fmanzano@ual.es

Received: 2 May 2019; Accepted: 28 May 2019; Published: 31 May 2019

Abstract: Background: Malaria is one of the infectious diseases of greatest interest to the scientific community and of greatest concern to international health authorities. Traditionally, the focus has been on Plasmodium falciparum, the parasite that causes the most severe form of the disease in Africa. However, in the last twenty years, the Plasmodium vivax parasite, responsible for a large number of cases in Latin America, the Middle East, South and Southeast Asia, the Horn of Africa, and Oceania, has also generated enormous interest due, among other things, to the published evidence that it can cause severe malaria. Methods: In this paper, the international scientific publication on malaria and P. vivax has been analyzed using the Scopus database to try to define global trends in this field of study. Results: It has been shown that events such as the emergence of resistance to certain drugs can break a trend. The important role of non-malaria-endemic countries such as the USA or Switzerland in malaria research is also evident. Conclusions: International cooperation will be essential for the eradication of the disease. Moreover, in this sense, the general vision given by the bibliometric analysis of malaria caused by P. vivax is fundamental to paint the picture regarding the current situation and encourage international cooperation and control efforts.

Keywords: malaria; Plasmodium vivax; chloroquine; Plasmodium falciparum; Scopus

1. Introduction

Malaria is a disease that has affected the human population since ancient times. Today, it remains one of the infectious diseases with the highest morbidity and mortality rates, with 219 million estimated cases occurred worldwide in 2017, according to WHO, and half a million people dying each year worldwide, many of them children under five [1]. Because of this, a series of international programs have been initiated that aim to reduce and eradicate malaria, such as malERA, a research agenda for malaria elimination and eradication [2]. Human malaria can be caused by different species of the Plasmodium parasite. P. falciparum and P. vivax are the most important, with more than 95% of the cases diagnosed in the world, but there are others such as P. malariae, P. knowlesi, P. ovale wallikeri, and P. ovale curtisi [3].

P. falciparum is the most severe form of the disease in Africa, where more than 90 percent of all malaria cases occur. For this reason, this is the best-characterized species [4]. However, in recent years, the infections caused by P. vivax are increasing in significance because of evidence for severe malaria P. vivax infection [5]. In addition, P. vivax has recently received a large amount of attention, as it is the species with the largest geographical distribution, being reported fundamentally in Latin America, the
Middle East, South and Southeast Asia, the Horn of Africa and Oceania [6]. This attention received by *P. vivax* is not only scientific, as illustrated by the increase in the number of published articles on this subject, but has also increased interest at the health level, trying to improve the diagnosis of malaria by these species or the specific treatments. The last factor that makes *P. vivax* a parasite of growing interest is its very hard elimination, with a high number of symptomatic relapses in malaria patients [7].

The malaria parasite is transmitted by a female *Anopheles* mosquito, inoculating sporozoites into the human host [8]. The sporozoites reach human liver cells, where they transform to give rise to another form called the merozoite. The merozoite reaches the erythrocytes, through the bloodstream, and multiples to produce new merozoites. Some of the merozoites released after the breakage of the erythrocytes are transformed into gametocytes. If the *Anopheles* mosquito bites an infected individual, then this is how the merozoites re-enter it. Inside the mosquito, in its midgut, sexual reproduction takes place, generating zygotes and developing into oocysts. These, as they grow and break, release sporozoites that invade the mosquito’s salivary glands. The parasite will then in the proper form to infect a new individual [9]. A fundamental difference in the life cycle of *P. vivax* is that it can successfully finish its development cycle in the mosquito at lower temperatures and faster than *P. falciparum*.

The complexity of the parasite’s life cycle, its great genetic variability, and the numerous mechanisms it can develop to avoid the host’s immune response, make it very difficult to find a vaccine to suppress human malaria [10,11]. In addition, the biology of *P. vivax*, as opposed to *P. falciparum*, makes it harder to control and eliminate and is the main reason for the higher vectorial capacity of *P. vivax*. Other reasons are related to the presence of hypnozoites (latent hepatic forms), which lead to multiple relapses and low parasites densities, which in turn makes diagnosis difficult and delays treatments [12]. On the other hand, there are no suitable experimental models for the analysis of a hypothetical vaccine. Despite this, finding a vaccine to eradicate malaria caused by *P. vivax* has become a fundamental objective for the WHO and the scientific communities around the world.

Bibliometric analyses provide fundamental scientific tools allowing for objective quantification of a scientific fact. These show the level of current knowledge in a scientific field by the compilation of data obtained from bibliographic databases. Bibliometrics facilitate comprehension and elaborates a real image of the research activity. In this study, the analysis of the international scientific publication on malaria and *P. vivax* has been raised to establish worldwide trends. It is essential for defining the research lines in malaria and creating synergies in order to achieve the WHO objective of eradicating malaria [13].

2. Materials and Methods

The evolution of the electronic age has led to the development of numerous scientific databases on the World Wide Web, which offer search facilities on a particular issue. Among them, some allow the opportunity to analyze citations from published works. The main scientific databases covering medical terms are PubMed, Scopus, Web of Science, and Google Scholar. PubMed focuses essentially on medicine and biomedical sciences, while Scopus, Web of Science, and Google Scholar cover most scientific fields. Usually, bibliometric studies are based on the keywords indexed by the published works. The main differences between these databases are PubMed (no limit), Scopus (30), Web of Science (15), and Google Scholar (no limit). However, in indexed journals and conference proceedings, there is usually a limit of about 6 keywords per published work so the limit of 15 is considered adequate for bibliometric works. However, PubMed’s search function, which is designed to search for medical documents, are exceptional and offer a service that other search engines do not. In this database, the search results can only be sorted by general characteristics such as publication date or author, and therefore, this is not very useful to get an overview of a topic [14]. Nowadays, mainly Web of Knowledge and Scopus allow large-scale downloads of bibliographic information from indexed publications and so most of the worldwide bibliometric works are based on one of these two databases. Scopus is the database that indexes the largest number of publications and conference proceedings when compared to the other three databases mentioned. Elsevier’s Scopus database is currently the
largest abstract and citation database of peer-reviewed literature, and although another database, the Web of Science (WoS), is also available, it lists fewer titles whereas Scopus lists 84% of WoS titles compared to only 54% of Scopus titles listed by WoS [15,16].

Scopus is usually considered the largest abstract and citation database of peer-reviewed scientific literature in the world. It contains more than 35,000 titles belonging to more than 10,000 publishers. For this reason, in order to analyze who, how, where, and what is being researched in a given scientific field, the most commonly used option is to use this database. Thus, it is common to find bibliometric works in many scientific fields using Scopus [17–19]. In short, Scopus is the most effective search engine and provides an overview of the subject. For extensive and in-depth research in the area of life sciences and closely related topics, PubMed should be considered as well [14]. For this reason, Scopus was the database of choice for this analysis.

In this work, a full search of the Elsevier Scopus database was conducted using TITLE-ABS-KEY (malaria and vivax) as the search query. This resulted in 11,166 documents being obtained between 1916 and 2018, the last full year from Scopus database. It should be noted that varying the search criteria, or subsequent modifications of Scopus, can give significantly different results. That keywords entered by the author or publisher may not strictly conform to the subject matter of the articles should also be considered. Notwithstanding the previous, Scopus is considered a valid option for this type of analysis. In keyword analysis, terms with identical meanings were grouped together (e.g., Plasmodium vivax and P. vivax), and terms that do not contribute to this analysis were discarded (e.g., article). The aspects that have been studied are the progression in the number of publications per year, the distribution of publications by institutions and by country, and the keywords (Figure 1). For the detection of scientific communities, understood as the set of nodes connected to each other in a complex network, the software tool VOSviewer [20] (http://www.vosviewer.com/) was used. This software has been used to create graphs in which each institution is represented by a node and the connections between two nodes represent the collaboration between the two institutions represented.

![Methodology for searching the different analyses.](image)

Figure 1. Methodology for searching the different analyses.

3. Results and Discussion

3.1. Progression of Scientific Output

The search returned 11,166 documents. Figure 2 shows the evolution trend of the number of documents on Plasmodium vivax and malaria since the first article was published. As shown in Figure 2, the first article published on this is dated in 1916 [21]. This early entry in the first article shows the strong interest that the scientific community has placed on malaria over the years.
which pushed up the price of insecticides. Between the years 2002–2010, the increase in the number of manuscripts that are published in each country. The United States of America, United Kingdom, and India, top the ranking of publications, represent 75% of the total. Note that the same article may be signed by authors from different countries.

Figure 4 shows the data on a world map with colors identifying the number of manuscripts that are published in each country. The United States of America, United Kingdom, and India, top the ranking with 2528, 1439, and 1383 publications, respectively. To normalize the results, the data have been referenced to the population of each country, based on the 2018 statistics obtained from the website [25] (Table 1). In this case, it can be observed that there are 10 countries that publish at least 7 articles per
million inhabitants. These are (ranked from highest to lowest): Switzerland, Australia, Papua New Guinea, United Kingdom, Netherlands, Thailand, Belgium, France, United States, and Sri Lanka.

In relative terms, Switzerland very high scientific output is striking. This can be explained by two reasons. First, Switzerland must be considered an international power in innovation. It is no coincidence that the development of an effective malaria vaccine is taking place in the country. The pharmaceutical industry is well established in this country, and there are numerous public and private research and development institutions around this type of industry [26]. On the other hand, Switzerland is home to international agencies and institutions concerned with global health care. The Swiss Agency for Development and Cooperation (SDC), an agency of the Swiss federal administration responsible for coordinating cooperation and humanitarian aid activities, and the World Health Organization, whose headquarters are in Geneva, stand out in this regard.

Finally, Table 1 also reflects the relative wealth of each country based on the value of GDP per capita (IMF data). Thus, it can be observed that the 10 countries studied above are divided into two
groups. Seven high-income countries (Switzerland, Australia, United Kingdom, Netherlands, Belgium, France, and United States), with more than 40,000 GDP per inhabitant, and three low-income countries (Papua New Guinea, Thailand, and Sri Lanka), with less than 7000. The motivations in one or the other case are different. While in the former, the interest is purely scientific, for the latter it is a question of survival. In these three countries, malaria is an endemic disease, although in terms of survival, there is very little malaria in Thailand, and Sri Lanka has eliminated all malaria.

Table 1. Leading countries in terms of scientific research and publication in terms of population and wealth cited.

| Country          | Publications (N) | Population (P) (Mill. of Inhabitants) | N/P  | GDP Per Capita |
|------------------|------------------|----------------------------------------|------|----------------|
| United States    | 2528             | 329,093                                | 7682 | 62,332         |
| UK               | 1439             | 66,959                                 | 21,491 | 41,951        |
| India            | 1383             | 1,368,738                              | 1010 | 1965          |
| Thailand         | 948              | 69,306                                 | 13,678 | 6984          |
| Australia        | 773              | 25,089                                 | 30,812 | 56,920        |
| Brazil           | 718              | 212,393                                | 3381 | 8988          |
| France           | 559              | 65,481                                 | 8537 | 42,684        |
| Switzerland      | 427              | 8608                                   | 49,605 | 82,365        |
| China            | 353              | 1,420,062                              | 249  | 9476          |
| Colombia         | 321              | 49,850                                 | 6439 | 6580          |
| Japan            | 318              | 126,855                                | 2507 | 39,975        |
| Indonesia        | 315              | 269,536                                | 1169 | 3729          |
| Spain            | 299              | 46,441                                 | 6438 | 30,942        |
| South Korea      | 295              | 51,339                                 | 5746 | 32,256        |
| Germany          | 270              | 82,439                                 | 3275 | 48,872        |
| Netherlands      | 256              | 17,133                                 | 14,942 | 53,114        |
| Italy            | 215              | 59,217                                 | 3631 | 35,226        |
| Pakistan         | 206              | 204,596                                | 1007 | 1486          |
| Papua New Guinea | 205              | 8587                                   | 23,873 | 3028          |
| Malaysia         | 198              | 32,454                                 | 6101 | 11,247        |
| Ethiopia         | 192              | 110,136                                | 1743 | 781           |
| Iran             | 171              | 82,821                                 | 2065 | 5059          |
| Canada           | 162              | 37,280                                 | 4345 | 46,513        |
| Sri Lanka        | 158              | 21,019                                 | 7517 | 4425          |
| Belgium          | 153              | 11,563                                 | 13,232 | 48,603        |

Figure 5 shows the 13 institutions with at least 180 publications on malaria and \( P. \text{ vivax} \). Of these, four are from USA (Centers for Disease Control and Prevention, National Institutes of Health in Bethesda, National Institute of Allergy and Infectious Diseases, and Armed Forces Research Institute of Medical Sciences known as AFRIMS), three are from the UK (the University of Oxford, Nuffield Department of Clinical Medicine, and London School of Hygiene and Tropical Medicine), two are from Thailand (Mahidol University and Shoklo Malaria Research Unit), two are Brazilian (Fundacao Oswaldo Cruz and Universidade de Sao Paulo), and one is Indian (National Institute of Malaria Research of India). Note that there may be several affiliations within the same institution but the database considers them separately respecting the decision of the authors.

As mentioned above, these five countries along with Australia, are the most relevant in scientific publications on this topic. In addition, it is surprising that among these, there is also an institution from Papua New Guinea. This is the Papua New Guinea Institute of Medical Research, also known as PNGIMIR, that has the support of the World Health Organization (WHO). Figure 6 shows a distribution by communities of the main institutions. It can be observed that most institutions are grouped into a cluster whose central element is the faculty of tropical medicine of the Mahidol University (Thailand). Each line of union between the nodes represents the relationships established between the institutions. Thus, the relations are quite complex, and that they are observed not only between the different
elements of this large cluster but also with the other institutions of the two additional minority clusters. The two smaller clusters are made up of the Papua New Guinea Institute of Medical Research and the Swiss Tropical and Public Health Institute, in one, and the Medicines for Malaria Venture (MMV) in the other.

Figure 5. Main institutions in terms of scientific publication in malaria and *P. vivax*.

3.3. Keyword Analysis

In the analysis of the keywords, if one of them does not contribute anything to the study then it must be eliminated, e.g., “article.” In the second place, all terms that refer to the same concept must be grouped together, e.g., “*Plasmodium vivax*” and “*P. vivax*.” Figure 7 shows, using a word cloud, that the 32 keywords are in more than 1000 publications on malaria and *P. vivax*. In Figure 7, the relative size of each word is directly proportional to the number of times the keyword is present in the analyzed documents. As expected, *Plasmodium vivax*, human, and malaria, with 9826, 9428, and 8572, respectively, stand out.
Among the 32 keywords with more than 1000 presences in the analyzed articles are two drugs, chloroquine and primaquine, present in 2395 and 1682 documents, respectively. Furthermore, 11 other keywords related to drugs are among the 160 most used keywords. These are ranked in order of their importance: quinine, mefloquine, artemisinin, artesunate, pyrimethamine, doxycycline, fansidar (actually, the trade name for sulfadoxine/pyrimethamine), artemether plus benflumetol, sulfadoxine, proguanil, and amodiaquine. Figure 8 shows that since 1946, the evolution of malaria and \textit{P. vivax} research in relation to the different drugs. As already mentioned, the most important drug as keyword is chloroquine. Although considering only the last 5 years, the relative importance of primaquine is similar. This is because the WHO indications are that, in areas where chloroquine maintains its efficacy, this must be the drug used against malaria caused by \textit{P. vivax} [27]. On the other hand, primaquine has been shown to be highly effective in acting against hypnozoites, which are the predominant latent forms in \textit{P. vivax}. Furthermore, until recently, it was the only approved hypnozoiticide. For these reasons, to avoid relapses caused by it, the administration of primaquine is appropriate although there are threats from incomplete compliance with standards and the development of tolerance, although the real problem in the supply of this drug is its potential toxicity due to the deficiency, in patients, of the enzyme G6PD [28]. Figure 8 also shows the relative importance of different drugs at any given time. For example, mefloquine had a relative maximum in 2004 and how, subsequently, it has been losing relevance due to its scarce further use. On the contrary, artemisinin—and its derivative artesunate—has a fundamental importance in recent years, being the most effective drug against all forms of multidrug-resistant \textit{P. falciparum} [29]. Other drugs such as fansidar (sulfadoxine/pyrimethamine) or proguanil have practically no importance in recent publications on malaria and \textit{P. vivax}, highlighting the trend in the use of these in the treatment of the disease.
Also, it can be seen that the five species of *Plasmodium* that have been shown to cause malaria in humans (*P. vivax*, *P. falciparum*, *P. malariae*, *P. ovale*, and *P. knowlesi*) are among the 100 most used keywords. Finally, five countries are also present among the most important keywords: India, Thailand, Brazil, China, and Papua New Guinea. These are countries where malaria caused by *P. vivax* is endemic and they are at the focus of many efforts by the international scientific community to eliminate malaria.

4. Conclusions

Malaria is still one of the world’s major health problems today; both for its extent and for the priority consideration it has received from public and private organizations concerned with human health. For this reason, malaria is a topic that is increasingly published in scientific journals with impact factors. Moreover, within this theme, malaria caused by *P. vivax* is currently receiving special interest. The present study has shown that the growth in the number of publications is exponentially curved, demonstrating the enormous interest that *P. vivax* causes in the international scientific community. This trend is only interrupted by two moments in history when interest in malaria has broken the norm. Thus, it becomes clear how bibliometric analysis of a given subject allows fundamental facts or moments to be identified. In this specific case, it is the discovery of a drug, chloroquine, which proved to be useful in the fight against malaria, and the rebound in the number of malaria cases in the early 1970s due to the relaxation of the alert level in the international scientific community.

On the other hand, the most important countries in terms of scientific publication have been identified. In global terms, the USA, UK, and India stand out above the rest. However, when a more exhaustive analysis is carried out, and both the population and the wealth of the country are considered, it is observed that there are other countries of greater relative importance. Thus, Switzerland has been found to be the country that devotes the most relative effort to the fight against malaria. This is no coincidence. This country is a biotechnological benchmark and is home to many international public and private bodies that have been working to eliminate malaria for decades. The identification of countries such as Switzerland highlights the importance of combining technological, scientific, and political efforts of public and private initiatives in the fight against the disease. This union of efforts is evidenced by the study of the relationships between the most outstanding institutions and scientists in the field of malaria and *P. vivax*. In most cases, there are collaborations that dilute the borders between rich countries that are devoting efforts to fight malaria, such as the UK, and countries where the disease is a real public health problem, such as Thailand.
Bibliometric studies not only give an overview of the current state of a scientific issue but can help to understand policy decisions and shape future scientific research. For this reason, an analysis of the keywords has been carried out allowing us to identify the main sectors in which the greatest efforts are being focused on research on malaria and *P. vivax*. Of these, studies on antimalarials stand out. The elements that define the lines of international economic investment and objectives in research projects are the progression of trends, the recommendations of the WHO, the updating of studies on the effectiveness of drugs, and the existence of resistance to them. It is important to have a general view of the subject in order to focus on the strategies that are still valid and to open up new promising lines of research.

**Author Contributions:** Conceptualization, J.A.G.-C. and F.M.-A.; methodology, J.A.G.-C., J.C.-C., and C.M.-V.; formal analysis, J.A.G.-C. and F.M.-A.; investigation, J.A.G.-C., L.G.-C., and C.M.-V.; writing—original draft preparation, J.A.G.-C. and J.C.-C.; writing—review and editing, L.G.-C., F.M.-A., and C.M.-V.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Ashley, E.A.; Pyae Phyo, A.; Woodrow, C.J. Malaria. *Lancet* 2018, 391, 1608–1621. [CrossRef]
2. Rabinovich, R.N.; Drakeley, C.; Djimde, A.A.; Hall, B.F.; Hay, S.I.; Hemingway, J.; Kaslow, D.C.; Noor, A.; Okumu, F.; Steketee, R.; et al. malERA: An updated research agenda for malaria elimination and eradication. *PLoS Med.* 2017, 14, e1002456. [CrossRef] [PubMed]
3. Garrido-Cardenas, J.A.; Gonzalez-Ceron, L.; Manzano-Agugliaro, F.; Mesa-Valle, C. *Plasmodium* genomics: An approach for learning about and ending human malaria. *Parasitol. Res.* 2018, 118, 1–27. [CrossRef] [PubMed]
4. Roca-Feltner, A.; Carneiro, I.; Smith, L.; Schellenberg, J.R.A.; Greenwood, B.; Schellenberg, D. The age patterns of severe malaria syndromes in sub-Saharan Africa across a range of transmission intensities and seasonality settings. *Malar. J.* 2010, 9, 282. [CrossRef]
5. Baird, J.K. Neglect of *Plasmodium vivax* malaria. *Trends Parasitol.* 2007, 23, 533–539. [CrossRef]
6. Battle, K.E.; Karhunen, M.S.; Bhatt, S.; Gething, P.W.; Howes, R.E.; Golding, N.; Van Boeckel, T.P.; Messina, J.P.; Shanks, G.D.; Smith, D.L.; et al. Geographical variation in *Plasmodium vivax* relapse. *Malar. J.* 2014, 13, 144. [CrossRef] [PubMed]
7. White, N.J. Determinants of relapse periodicity in *Plasmodium vivax* malaria. *Malar. J.* 2011, 10, 297. [CrossRef]
8. Smith, R.C.; Vega-Rodriguez, J.; Jacobs-Lorena, M. The *Plasmodium* bottleneck: Malaria parasite losses in the mosquito vector. Mem. Inst. Oswaldo Cruz 2014, 109, 644–661. [CrossRef]
9. Wiser, M. *Plasmodium* Life Cycle. Available online: http://www.tulane.edu/~wiser/malaria/mal_lc.PDF (accessed on 7 October 2011).
10. Tuju, J.; Kamuyu, G.; Murungi, L.M.; Osier, F.H.A. Vaccine candidate discovery for the next generation of malaria vaccines. *Immunology* 2017, 152, 195–206. [CrossRef]
11. Flores-Alanis, A.; Gonzalez-Ceron, L.; Santillan, F.; Ximenez, C.; Sandoval, M.A.; Cerritos, R. Temporal genetic changes in *Plasmodium vivax* apical membrane antigen 1 over 19 years of transmission in southern Mexico. *Parasites Vectors* 2017, 10, 217. [CrossRef] [PubMed]
12. Olliaro, P.L.; Barnwell, J.W.; Barry, A.; Mendis, K.; Mueller, I.; Reeder, J.C.; Shanks, G.D.; Snounou, G.; Wongsrichanalai, C. Implications of *Plasmodium vivax* Biology for Control, Elimination, and Research. *Am. J. Trop. Med. Hyg.* 2016, 95, 4–14. [CrossRef] [PubMed]
13. WHO. Global Technical Strategy for Malaria 2016–2030; World Health Organization: Geneva, Switzerland, 2015.
14. Tober, M. PubMed, ScienceDirect, Scopus or Google Scholar–Which is the best search engine for an effective literature search in laser medicine? *Med. Laser Appl.* 2011, 26, 139–144. [CrossRef]
15. Mongeon, P.; Paul-Hus, A. The journal coverage of Web of Science and Scopus: A comparative analysis. * Scientometrics* 2016, 106, 213–228. [CrossRef]
16. Gavel, Y.; Iselid, L. Web of Science and Scopus: A journal title overlap study. *Online Inf. Rev.* 2008, 32, 8–21. [CrossRef]
17. Boehm, K.; Berger, B.; Ostermann, T.; Heusser, P. Placebo effects in medicine: A bibliometric analysis. *JRSM Open* 2016, 7, 205427041664389. [CrossRef]
18. Kakouris, A.; Georgiadis, P. Analysing entrepreneurship education: A bibliometric survey pattern. *J. Glob. Entrep. Res.* 2016, 6, 6. [CrossRef]
19. Garrido-Cardenas, J.A.; Mesa-Valle, C.; Manzano-Agugliaro, F. Human parasitology worldwide research. *Parasitology* 2018, 145, 699–712. [CrossRef] [PubMed]
20. Van Eck, N.J.; Waltman, L. Software survey: VOSviewer, a computer program for bibliometric mapping. *Scientometrics* 2010, 84, 523–538. [CrossRef]
21. King, W.V. experiments on the development of malaria parasites in three american species of anopheles. *J. Exp. Med.* 1916, 23, 703–716. [CrossRef]
22. Baird, J.K. Resistance to chloroquine unhinges vivax malaria therapeutics. *Antimicrob. Agents Chemother.* 2011, 55, 1827–1830. [CrossRef] [PubMed]
23. Sina, B. Focus on *Plasmodium vivax*. *Trends Parasitol.* 2002, 18, 287–289. [CrossRef]
24. Gimenez, E.; Manzano-Agugliaro, F. DNA Damage Repair System in Plants: A Worldwide Research Update. *Genes* 2017, 8, 299. [CrossRef]
25. Countries in the World by Population (2019). Available online: http://www.worldometers.info/world-population/population-by-country (accessed on 31 May 2019).
26. Santiago, M.G.; Bucher, H.C.; Nordmann, A.J. Marketing of pharmaceutical products in Switzerland. *BMC Med. Inform. Decis. Mak.* 2008, 8, 61.
27. Price, R.N.; von Seidlein, L.; Valecha, N.; Nosten, F.; Baird, J.K.; White, N.J. Global extent of chloroquine-resistant *Plasmodium vivax*: A systematic review and meta-analysis. *Lancet Infect. Dis.* 2014, 14, 982–991. [CrossRef]
28. Fernando, D.; Rodrigo, C.; Rajapakse, S. Primaquine in vivax malaria: An update and review on management issues. *Malar. J.* 2011, 10, 351. [CrossRef] [PubMed]
29. Tilley, L.; Straimer, J.; Gnäig, N.F.; Ralph, S.A.; Fidock, D.A. Artemisinin Action and Resistance in *Plasmodium falciparum*. *Trends Parasitol.* 2016, 32, 682–696. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).